Women's Health Deal Benchmarks
Benchmark deal terms for endometriosis, uterine fibroids, menopause, and fertility treatments. Women's health has seen increasing deal activity as novel mechanisms address historically underserved conditions. Benchmarks derived from 93 verified transactions.
93
Total Deals
$1.3B
Avg Upfront
5
Deal Types
100%
Terms Disclosed
Deal Structure Distribution
42
license
32
acquisition
13
collaboration
4
option
0
co development
Recent Deals with Disclosed Terms
| Parties | Type | Upfront | Total Value | Date |
|---|---|---|---|---|
Organon → Sun Pharmaceutical Industries Organon (whole company) | acquisition | $11.8B | $11.8B | Apr 2026 |
Sage Therapeutics → Supernus Pharmaceuticals Zurzuvae (zuranolone) acquisition | acquisition | $561M | $795M | Jun 2025 |
Jiangsu Hengrui Pharmaceuticals (恒瑞医药) → Merck KGaA, Darmstadt, Germany SHR7280 | license | $16M | — | Apr 2025 |
Gynesonics → Hologic Sonata System | acquisition | $350M | $350M | Jan 2025 |
Kissei Pharmaceutical → Theramex Linzagolix (YSELTY) | license | $50M | $200M | Dec 2024 |
Organon → Samsung Bioepis endometriosis | license | $200M | $800M | Oct 2024 |
Dermavant/Roivant → Organon Vtama (tapinarof) acquisition | acquisition | $175M | $1.2B | Sep 2024 |
Metabolomics Diagnostics → Trinity Biotech PrePsia | acquisition | $1M | $1M | Sep 2024 |
Insilico Medicine → Menarini/Stemline MEN2312 (KAT6A inhibitor) | license | $12M | $500M | Jan 2024 |
Evofem Biosciences → Aditxt Phexxi | acquisition | $25M | $25M | Nov 2023 |
Benchmark Your Women's Health Deal
Get instant benchmarks for upfront payments, milestones, and royalties based on 93 verified women's health transactions.
Women's Health Deal Benchmarking FAQ
Why is women's health deal activity increasing?
Women's health has been historically underserved by pharma, but new mechanisms (GnRH antagonists, non-hormonal approaches) and increased venture funding have driven a deal-making resurgence. The approval of oral GnRH antagonists for endometriosis and fibroids validated the commercial opportunity, spurring follow-on partnerships.
What are typical deal terms for endometriosis licensing agreements?
Endometriosis deals typically feature upfronts of $20M-$100M for clinical-stage assets, with total deal values of $300M-$1B. Non-hormonal approaches command premium terms due to differentiation from established GnRH therapy. Royalties range 10-18% depending on the stage and competitive positioning.
How do fertility technology deals differ from traditional pharma licensing?
Fertility deals increasingly involve technology platforms (AI-driven embryo selection, in vitro maturation, genetic testing) rather than traditional drug licensing. These deals often feature lower upfronts but equity participation and revenue-sharing structures, reflecting the medtech-pharma hybrid nature of fertility innovation.